←
Dr. Brad Reinfeld, MD PhD3,954 posts
Dr. Brad Reinfeld, MD PhD avatar

Dr. Brad Reinfeld, MD PhD

@BReinfeld

MSKCC Oncology Fellow, Former Vanderbilt MSTP/UCLA Intern. Bass player in the CheckPoints. Physician-scientist studying metabolism. Views are my own! 🏳️‍🌈🩺

◷ Joined February 2012
Aponia_Analytics avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Aponia_Analytics@AponiaAnalytics·Nov 17

🦉Cancer Immunotherapy: More Than 1,000 Antigen Candidates in Melanoma A molecular atlas of cutaneous melanoma has revealed a substantial repertoire of potential immune targets, while exposing aspects of tumor biology that conventional genomic profiling may miss. The study examined tumors from 183 patients using 13 molecular measurement layers, integrating genomic, transcriptomic, proteomic, immunopeptidomic, and metabolomic data. Direct analysis of peptides presented for immune recognition identified more than 1,000 candidate tumor antigens. Protein modifications also revealed associations with immune activity and patient survival that were not apparent from protein abundance measurements alone. The atlas offers a resource for antigen discovery, biomarker development, and future therapeutic research. However, identifying a presented peptide does not establish its immunogenicity or suitability as a safe vaccine or cellular-therapy target. aacrjournals.org/cancerdisco…

Post attachment
Cell Press avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Cell Press@CellPressNews·Nov 17

Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells hubs.li/Q04DRpgw0 Article highlight from @CellStemCell

Bernie Bochner, MD avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Bernie Bochner, MD@bbmdmsk·Nov 17

Our team @MSKCancerCenter @RockefellerUniv are excited to see our completed #bladderCA trial using intravesical anti-CD40 targeting in press. Ongoing anti-CD40 PH3 trial for NMIBC opened! @UrologyMSK @juanosoriomd @DrRosenbergMSK @eugene_pietzak @UroOnc aacrjournals.org/clincancerr…

Nature Metabolism avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Nature Metabolism@NatMetabolism·Nov 16

Plasma proteomics identifies insulin resistance signatures predictive of cardiometabolic disease risk dlvr.​it/TWM8XS

Post attachment
Oncogene Journal avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Oncogene Journal@oncogenejournal·Nov 16

A new study identifies B3GNT9 as a key engine of glioblastoma invasion, linking altered glycosylation and fatty acid metabolism to tumour spread. nature.com/articles/s41388-0…

NEJM avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
NEJM@NEJM·Nov 12

In a trial of the individualized neoantigen therapy intismeran in patients with resected stage IIB to IV melanoma, 24-month recurrence-free survival was 82.2% with intismeran–pembrolizumab and 70.0% with pembrolizumab alone. Full phase 3 INTerpath-001 trial results: nej.md/4sTuIgb Editorial: Cancer Vaccines — From Treatment to Prevention nej.md/3UIPp1K

Post attachment
Jamie Blundell avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Jamie Blundell@jrblundell·Nov 11

How do cancers emerge from healthy tissue? In @Nature today: leukaemia evolving in yearly blood samples up to 15 yrs before AML. First driver by age 20; each new driver multiplies growth 2–3×. A remarkably simple set of mathematical rules recapitulate it. nature.com/articles/s41586-0…

Cancer Cell avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Cancer Cell@Cancer_Cell·Nov 11

A stroma-sensing TGF-β blockade reprograms CAF-myeloid niches to induce durable tumor immunity dlvr.​it/TWHBk9

Post attachment
Antonio Ocejo avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Antonio Ocejo@ja_ocejo·Nov 10

📚 Recently wrote this piece for #ASCOConnection on learning during oncology fellowship—and how to keep building those skills beyond training. A lot of it comes from advice I’ve picked up from mentors and attendings along the way, plus a few lessons from figuring out what has worked (and not worked) for me. Hope it’s helpful to other fellows navigating the same process! 🔗 connection.asco.org/do/build… #MedEd #HemeOnc #OncTwitter

Post attachment
Neil Stone avatar
⟳ Dr. Brad Reinfeld, MD PhD retweeted
Neil Stone@DrNeilStone·Nov 9

New NEJM trial of 1,880 people over 70: Those who stopped their statins 12.7% had a heart attack, stroke or died Compared to 9.2% who kept taking them nejm.org/doi/full/10.1056/NE…